The impact factor of British Journal of Cancer sits at 7.5 for 2023. That number lands it firmly in the top tier of oncology journals — but if you're only looking at the number, you're missing the story.
I've watched researchers refresh the Journal Citation Reports page every June like it's a lottery draw. Some years the number ticks up. Some years it dips. And every year, someone in a lab meeting asks: "Should we submit here or hold out for something higher?
Here's the thing — that question reveals a misunderstanding of what this journal actually is, who reads it, and why the impact factor only tells part of the story.
What Is British Journal of Cancer
British Journal of Cancer (BJC) has been around since 1947. That's not a typo — it launched two years after World War II ended, when cancer research was still figuring out that smoking caused lung cancer. The journal is owned by Cancer Research UK, one of the world's largest independent cancer research organizations, but it's published by Nature Portfolio (formerly Nature Publishing Group).
That ownership structure matters. Cancer Research UK plows surplus revenue back into research funding. That's why no shareholders. No profit extraction. The journal exists to advance the field, not to maximize margins.
Scope and positioning
BJC sits in a sweet spot. It's not a niche journal focused on a single cancer type or methodology. The common thread? It's not a broad-spectrum journal like Nature or Science. It publishes original research across the entire oncology spectrum — basic science, translational work, clinical trials, epidemiology, and prevention. Rigor and relevance to cancer biology or patient outcomes.
The journal publishes roughly 200–250 papers per year. That's selective but not boutique. Compare that to some journals pumping out 1,000+ papers annually — the acceptance rate at BJC hovers around 15–20%, which means getting in is a genuine achievement without being a lottery.
Who actually reads it
This is where the impact factor conversation usually goes off the rails. People treat the IF as a prestige score. But BJC's readership tells a different story.
The journal reaches oncologists, cancer biologists, epidemiologists, pharmacologists, and clinical trialists. It's read by people writing grants, designing trials, and deciding which mechanisms to chase in the lab. A paper in BJC doesn't just collect citations — it gets into the hands of people who can actually use it.
Why the Impact Factor Matters (And Why It Doesn't)
Let's be honest — the impact factor matters. Grant committees look at it. Practically speaking, promotion committees look at it. Because of that, phD students applying for postdocs look at it. The 7.5 number signals: this journal publishes work that gets cited.
But the number has quirks worth understanding.
The citation window problem
The standard impact factor uses a two-year citation window. A landmark trial published in BJC might not hit its citation stride until year three or four. Papers published in 2021–2022 cited in 2023. For a field like oncology, where clinical translation takes years, that's blunt. Basic science papers often have longer citation half-lives than the two-year window captures.
BJC's five-year impact factor? It's 8.2. That's a more honest signal for this field.
The review article effect
Review articles rack up citations fast. BJC publishes reviews, but they're selective — usually invited, often from leaders in the field. Original research takes longer. This inflates the IF somewhat, but it also means the reviews are genuinely useful, not just citation bait.
What the number doesn't capture
The impact factor doesn't tell you:
- Whether the journal's peer review actually improves your paper (at BJC, it usually does)
- How fast the editorial process moves (BJC averages ~3 weeks to first decision)
- Whether the audience matches your work (critical for translational research)
- The journal's reputation among your specific subfield* (a pancreatic cancer researcher cares about different journals than a lymphoma researcher)
I've seen papers with 50 citations in a "lower IF" journal outperform papers with 15 citations in a "higher IF" journal — because the right people read the former.
How the Journal Actually Works
If you're considering submitting, understanding the machinery helps.
Editorial structure
BJC has a Editor-in-Chief (currently Professor Karen Vousden) supported by a team of Senior Editors and Associate Editors covering different domains — molecular oncology, clinical trials, epidemiology, prevention, etc. These are active researchers, not full-time professional editors. They know the field because they live in it.
The review process
First decision typically comes within 3 weeks. In practice, that's fast for a journal of this caliber. If the paper clears the editorial triage (scope, baseline quality, novelty), it goes to 2–3 reviewers. The journal uses single-blind review — reviewers know authors, authors don't know reviewers.
Here's what experienced authors know: BJC reviewers tend to be thorough but fair. And they'll ask for additional experiments if the claim demands it, but they won't ask for "one more experiment" just to be difficult. The editorial team pushes back on unreasonable requests.
Want to learn more? We recommend acs award for team innovation 2018 recipients affiliated institutions and does a proton have a positive charge for further reading.
Revision and acceptance
Major revisions get a second round of review. That said, minor revisions often get editorial acceptance. On the flip side, the journal publishes "Accepted Articles" online within days of acceptance — the final typeset version follows in the next issue. This means your work is citable fast.
Open access options
BJC is a hybrid journal. You can publish open access (gold OA) for an article processing charge — currently £3,690 / $4,890 / €4,390. Or you can publish subscription-access with a 12-month embargo before the paper becomes free. Cancer Research UK has read-and-publish agreements with many institutions (UK, Germany, Norway, others) that cover the APC.
If your funder mandates immediate OA, check whether your institution has a deal. It's worth a 30-second email to your library.
Common Mistakes Researchers Make With BJC
I've watched smart people make the same errors repeatedly. Here are the big ones.
Mistake 1: Treating it as a "backup journal"
"Nature rejected us, let's try BJC." This mindset shows in the cover letter and the manuscript. BJC editors can smell a demoted submission. The journal deserves a tailored submission — a cover letter that explains why this* audience needs this* finding, not a generic "we believe this is suitable for your journal.
Mistake 2: Underestimating the clinical relevance bar
BJC publishes basic science. On the flip side, a resistance mechanism? Does this suggest a biomarker? "We discovered protein X regulates pathway Y" isn't enough. Now, the paper needs to answer: so what for cancer? A therapeutic target? But even mechanistic papers need a clear line to cancer relevance. Papers that don't make this explicit get rejected at the editorial desk.
Mistake 3: Ignoring the statistical guidelines
BJC has specific statistical reporting requirements — CONSORT for trials, REMARK for biomarkers, ARRIVE for animal studies. It's not bureaucracy; it's reproducibility. Also, manuscripts that ignore these get bounced before review. The journal takes this seriously.
Mistake 4: Weak data availability statements
The journal requires data availability statements. Now, "Data available on request" often isn't sufficient anymore. Reviewers and editors increasingly expect deposition in public repositories (GEO, ArrayExpress, Figshare, Zenodo) with accession numbers in the manuscript. Plan for this before* submission.
Mistake 5: Treating the cover letter as an afterthought
The cover letter is read by the Editor-in-Chief or a Senior Editor before* they decide whether to send for review. It
needs to be compelling, concise, and persuasive. But a weak cover letter can kill your chances before the manuscript even reaches reviewers. Plus, use it to frame your work in the context of BJC’s mission: translational relevance, mechanistic depth, and clinical potential. Avoid form letters.
Final Tips for Success
BJC editors appreciate manuscripts that respect their editorial priorities. Here’s how to align with them:
- Start with a strong rationale. Open your cover letter with a clear statement of how your work addresses a gap in cancer biology or therapy. Editors want to see immediate relevance, not just incremental findings.
- Highlight translational potential. Even basic science papers should connect to diagnostics, biomarkers, or mechanistic insights with therapeutic implications. Be explicit.
- Follow formatting rules meticulously. BJC uses a standardized template for submissions. Deviations—like incorrect section headings or figure labels—create unnecessary delays. Use the “Preparation Guidelines” as a checklist.
- Anticipate reviewer concerns. Address potential limitations proactively in your manuscript. If your model system has known constraints, acknowledge them and justify their use. Reviewers will scrutinize weaknesses, so preempt them.
- Build a diverse, high-impact author team. BJC values interdisciplinary collaboration. Including clinicians, statisticians, or bioinformaticians strengthens your paper’s credibility and breadth.
The Bigger Picture
BJC isn’t just a journal—it’s a platform for advancing cancer research with real-world impact. Its reputation for rigorous, clinically relevant science means your work will be judged not just on novelty, but on its potential to influence both the lab and the clinic.
Submitting to BJC requires precision, persistence, and a mindset of advocacy. Think about it: craft a submission that speaks directly to the journal’s strengths, anticipate every hurdle, and position your research as a bridge between discovery and application. If you do this right, BJC won’t just publish your paper—it will amplify its reach.
In the end, success at BJC isn’t about luck. It’s about preparation, clarity, and a deep understanding of what the journal—and its readers—truly value. Get it right, and your science will resonate far beyond the pages.
